Zoetis

ZTS

Market cap $56.5B

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Lenivia is a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties to nerve growth factor (NGF), recognized as an important mediator of pain and inflammation. Lenivia is built on a decade of s.

As the animal health industry navigates a rapidly evolving landscape, companies are increasingly challenged to maintain their competitive edge through innovation and strategic adaptation.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. Kristin Peck, Chief Executive Officer and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. Investors and other interested parties can access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presen.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025, featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Executive Vice President and Chief Financial Officer; Rob Polzer, Ph.D., Executive Vice President and President of Research and Development; and Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic), Senior Vice President of Global Therapeutics. As previously announced, Dr. Esch will succeed Dr.

Downtrodden names expected to come roaring back include Adobe, Block and Salesforce.

Both stocks trade at once-in-a-decade low valuations and have all-time high dividend yields. Each company leads in its niche, but both are battling through minor challenges.

Zoetis (ZTS) the world's largest animal-health company, develops and manufactures medicines, vaccines, and diagnostics for both pets and livestock. The stock has come under pressure in recent months as softer clinic traffic, uneven companion-animal demand, and a narrowed full-year outlook weighed on sentiment.

The steep increase in pet healthcare costs have doubled over the past five years, according to NPR.

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Zoetis (ZTS). But which of these two stocks is more attractive to value investors?

Bad press has weighed on UnitedHealth Group and Zoetis. UnitedHealth Group faces controversy and investigations, but will likely survive and remain a key cog in America's healthcare system.